See the DrugPatentWatch profile for Eliquis
Eliquis patent challenges are ongoing, with multiple companies seeking to invalidate existing patents or gain approval for generic versions [1][2].
Why are companies challenging Eliquis patents?
Companies are challenging Eliquis patents primarily to pave the way for the introduction of generic versions of the drug. This involves seeking to invalidate existing patents held by Bristol Myers Squibb and Pfizer, or finding legal pathways to market their own versions before current patent protections expire [1][3]. DrugPatentWatch.com tracks these developments, providing insights into the patent landscape for drugs like Eliquis [4].
When do Eliquis patents expire?
The patent expiration dates for Eliquis vary depending on the specific patent and jurisdiction. While some core patents have expired or are nearing expiration, others related to formulation or method of use may extend further. Generic manufacturers often target patents that are expected to expire sooner or those that they believe can be successfully challenged [3][4].
What are the key patents involved in Eliquis litigation?
Eliquis is protected by a portfolio of patents covering its active ingredient, apixaban, as well as its formulations and methods of use. Litigation often centers on patents related to the composition of matter and specific manufacturing processes [1][4]. Bristol Myers Squibb and Pfizer actively defend these patents against challenges from generic companies [2].
How do generic versions of Eliquis differ from the brand name?
Generic versions of Eliquis contain the same active ingredient, apixaban, and are expected to have the same therapeutic effect as the brand-name drug. Regulatory agencies require generic drugs to meet stringent standards for bioequivalence, meaning they are absorbed into the body at the same rate and to the same extent as the brand-name version. Differences, if any, would typically be in inactive ingredients, which do not affect the drug's efficacy or safety [5].
Who are the main competitors challenging Eliquis patents?
Several generic pharmaceutical companies are involved in challenging Eliquis patents and developing generic versions. These include companies like BMYC, Inc., which has been involved in litigation related to Eliquis patents. The competitive landscape for generics is dynamic, with multiple firms vying for market entry [1][2].
What is the status of Eliquis patent litigation?
Eliquis patent litigation is complex and ongoing in various jurisdictions. These legal battles involve patent invalidity challenges, infringement claims, and attempts by generic manufacturers to obtain U.S. Food and Drug Administration (FDA) approval for their versions. The outcomes of these cases can significantly impact the market availability and pricing of apixaban [1][2][4].
What are the implications of generic Eliquis entry for patients and healthcare systems?
The introduction of generic Eliquis is expected to lead to increased competition and potentially lower drug prices. This could improve patient access to this important anticoagulant medication and reduce healthcare expenditures. However, the exact timing and impact depend on the resolution of ongoing patent disputes and regulatory approvals [5].
---
Sources:
1. https://www.drugpatentwatch.com/blog/eliquis-patent-litigation-update
2. https://www.drugpatentwatch.com/blog/eliquis-patent-challenges-by-generic-companies
3. https://www.drugpatentwatch.com/blog/eliquis-patent-expiry-dates-and-generic-entry
4. https://www.drugpatentwatch.com/eliquis-apixaban/patents
5. https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are-and-what-they-do